Fresh Tracks Therapeutics, Inc.
Fresh Tracks Therapeutics, Inc. (FRTX): 2 pipeline candidates · ~30 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
29.6 months
0% dilution
Lead: Phase 1
2 candidates
N/A
N/A
A transparent, data-derived signal for Fresh Tracks Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$10.9M
Quarterly Burn
$1.1M
Runway
29.6 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in Fresh Tracks Therapeutics, Inc.'s pipeline?
Fresh Tracks Therapeutics, Inc. (FRTX) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Fresh Tracks Therapeutics, Inc.'s lead drug candidate?
Fresh Tracks Therapeutics, Inc.'s most advanced tracked candidate is frtx-02 (Phase 1) for Autoimmune and inflammatory diseases.
What is Fresh Tracks Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Fresh Tracks Therapeutics, Inc. has approximately 29.6 months of cash runway.
Who is the CEO of Fresh Tracks Therapeutics, Inc.?
Fresh Tracks Therapeutics is the chief executive officer of Fresh Tracks Therapeutics, Inc. (FRTX).
Get the full picture on Fresh Tracks Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.